Abstract | OBJECTIVES: To assess the efficacy of urapidil, an alpha-blocker, on neurogenic bladder dysfunction in a placebo-controlled, double-blind trial. METHODS: 149 patients were randomly assigned to receive a placebo or 60 mg/day of urapidil for 4 weeks. The evaluation of efficacy included changes in urinary symptom scores and the results of a pressure/flow study. RESULTS: There were significant intergroup differences with regard to straining and the sum of urinary symptom scores, with the urapidil group showing marked improvements (p = 0.016 and p = 0.011, respectively). In the urapidil group, the average and maximum flow rates were unchanged, but the residual urine volume decreased significantly (p < 0.001) as compared with the baseline value. The pressure at maximum flow and the minimum urethral resistance decreased significantly (p = 0.040 and p = 0.040, respectively) in the urapidil group, and there was a significant (p = 0.005) intergroup difference with regard to pressure at maximum flow. There was also a significant (p < 0.001) inter-group difference with regard to the overall therapeutic effect. Side effects were noted in 2 patients treated with urapidil and 6 in the placebo group. CONCLUSION:
|
Authors | T Yamanishi, K Yasuda, Y Homma, K Kawabe, T Morita |
Journal | European urology
(Eur Urol)
Vol. 35
Issue 1
Pg. 45-51
(Jan 1999)
ISSN: 0302-2838 [Print] Switzerland |
PMID | 9933794
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Adrenergic alpha-Antagonists
- Piperazines
- urapidil
|
Topics |
- Adrenergic alpha-Antagonists
(therapeutic use)
- Adult
- Aged
- Aged, 80 and over
- Double-Blind Method
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Piperazines
(therapeutic use)
- Treatment Outcome
- Urinary Bladder, Neurogenic
(drug therapy, physiopathology)
- Urodynamics
(drug effects)
|